Napabucasin plus FOLFIRI in patients with previously treated metastatic colorectal cancer: Results from the open-label, randomized phase III CanStem303C study

by on 13 de febrer de 2023 with No hi ha comentaris
  • Shah, M. A., Yoshino, T., Tebbutt, N. C., Grothey, A., Tabernero, J., Xu, R. -., . . . Van Cutsem, E. (2022). Napabucasin plus FOLFIRI in patients with previously treated metastatic colorectal cancer: Results from the open-label, randomized phase III CanStem303C study. Clinical Colorectal Cancer. https://doi.org/10.1016/j.clcc.2022.11.002 (En premsa)

Deixa un comentari

L'adreça electrònica no es publicarà. Els camps necessaris estan marcats amb *